-+ 0.00%
-+ 0.00%
-+ 0.00%

BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual Meeting

Benzinga·05/22/2026 11:06:08
Listen to the news

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL.